Tech Company Financing Transactions
Variantyx Funding Round
On 2/27/2022, Variantyx raised $41.5 million in funding from New Era Capital Partners, 20/20 HealthCare Partners and Peregrine Ventures.
Transaction Overview
Company Name
Announced On
2/27/2022
Transaction Type
Venture Equity
Amount
$41,500,000
Round
Undisclosed
Investors
New Era Capital Partners (Lead Investor) (Gideon Argov)
Proceeds Purpose
The series C-2 funding round will be used to fuel company growth and launch newly developed solutions across all markets, with a focus on precision oncology.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
1671 Worcester Rd. 300
Framingham, MA 01701
USA
Framingham, MA 01701
USA
Phone
Website
Email Address
Overview
Variantyx is a CLIA/CAP laboratory providing Genomic Unity, a whole genome sequencing (WGS)-based testing program for diagnosis of rare inherited disorders. Its single method approach to comprehensive genetic testing identifies multiple variant types within a single patient sample to provide a unified clinical report.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Haim Neerman
Chief Operating Officer
Yaron Rachmany
Chief Scientific Officer
Noam Shomron
Vice President
Daryl Spinner
VP - Customer Service
Tomer Jackman
VP - Marketing
Jennifer Hogan
VP - Sales
Chris Zerwas
Browse more venture capital transactions:
Prev: 2/27/2022: Voila venture capital transaction
Next: 2/27/2022: Veho venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record tech company VC transactions. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs